Effect of the Xanthine Oxidase Inhibitor, Febuxostat, on WBC Count in Asymptomatic Hyperuricemia: Subanalysis of the Randomized PRIZE Study

CONCLUSIONS: Febuxostat therapy for 24 months modestly, but significantly, decreased WBC count in patients with asymptomatic hyperuricemia. This might potentially reflect a modest anti-inflammatory action of febuxostat in clinical settings.PMID:38220209 | DOI:10.5551/jat.64574

Source: Journal of Atherosclerosis and Thrombosis - January 14, 2024 Category: Cardiology Authors: Mitsuhide Takeshita Atsushi Tanaka Hisako Yoshida Ikuko Nakamura Yoshisato Shibata Shiro Hata Akifumi Kushiyama Masaaki Okutsu Tomoko Ishizu Koichi Node Source Type: research